Medicine Overview
Adult Dose
| Clinical Information | Administration Information |
|---|---|
|
Indication: Rheumatoid arthritis, psoriatic arthritis, and axial spondyloarthritis Age: Adult Condition: Inadequate response or intolerance to greater than 1 TNF blockers |
Dose: Oral – 15 mg Frequency: once daily Note: Consideration should be given to discontinuing treatment in patients with axial spondyloarthritis who have shown no clinical response after 16 weeks of treatment. |
|
Indication: Atopic Dermatitis Age: Adult (less than 65 years) Condition: Refractory moderate-to-severe disease not adequately controlled with other systemic therapies or if those therapies are inadvisable |
Dose: Oral – 15 mg Frequency: once daily initially Note: consider increasing to 30 mg once daily if an adequate response is not achieved. Discontinue if 30-mg dose if adequate response is not achieved. Use the lowest effective dose needed to maintain response. |
Child Dose
| Clinical Information | Administration Information |
|---|---|
|
Indication: Atopic Dermatitis Age: greater than 12 years Condition: Initial response |
Dose: Oral dose – 15 mg Frequency: once daily Note: by mouth (oral); Indicated for refractory moderate-to-severe atopic dermatitis in adults and pediatric patients aged greater than 12 years whose disease is not adequately controlled with other systemic therapies or if those therapies are inadvisable. |
|
Indication: Atopic Dermatitis Age: greater than 12 years Condition: Inadequate response |
Dose: Oral dose – 30 mg Frequency: once daily Note: by mouth (oral); Consider increasing to 30 mg once daily if an adequate response is not achieved; Discontinue if 30-mg dose if adequate response not achieved; Use lowest effective dose needed to maintain response. |
Renal Dose
| Clinical Information | Administration Information |
|---|---|
|
Indication: Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis, or Non-radiographic Axial Spondyloarthritis Condition: Mild, moderate, or severe renal impairment |
Dose: Tablet – Not specified Note: No dose adjustment necessary |
|
Indication: Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis, or Non-radiographic Axial Spondyloarthritis Condition: End-stage renal disease |
Dose: Tablet – Not specified Note: Not studied |
Administration
- Can take with or without food
- Take at same time each day
Side Effect
- Upper respiratory tract infection (URTI) (13.5%)
- Upper respiratory tract infection (URTI) (23-25%)
- Acne (10-16%)
- Nausea (3.5%)
- Neutropenia (1.1-2.4%)
- Lymphopenia (0.3-2.4%)
- Cough (2.2%)
- Elevated ALT (0.8-2.1%)
- Increased creatine phosphokinase (0.3-1.6%)
- Elevated AST (1-1.5%)
- Pyrexia (1.2%)
- Bronchitis (3.9%)
- Herpes simplex (1.4%)
- Acne (1.3%)
- Herpes zoster (1.1%)
- Herpes simplex virus (4-8%)
- Headache (6%)
- Increased blood creatine phosphokinase (5-6%)
- Cough (3%)
- Hypersensitivity (2-3%)
- Folliculitis (2-3%)
- Nausea (3%)
- Abdominal pain (2-3%)
- Pyrexia (2%)
- Increased weight (2%)
- Herpes zoster (2%)
- Influenza (2%)
- Fatigue (1-2%)
- Neutropenia (1-2%)
- Myalgia (1-2%)
- Influenza like illness (1-2%)
- Pneumonia
- Herpes zoster
- Herpes simplex (includes oral herpes)
- Oral candidiasis
- Anemia (Less than 0.1%)
- Tuberculosis
- Malignancies, excluding nonmelanoma skin cancer
- Venous thrombosis
- Elevated LDL
- Elevated HDL
Drug Interaction
Drug Interaction
| Drug Name | Risk Factors |
|---|---|
|
Strong CYP3A4 inhibitors (e.g. ketoconazole, itraconazole, posaconazole, voriconazole, clarithromycin)
|
Increased exposure
|
|
Strong CYP3A4 inducers (e.g. rifampin, phenytoin, St. John's Wort)
|
Decreased exposure
|
Disease Interaction
Disease Interaction
| Disease Name | Risk Factors |
|---|---|
|
No specific contraindications listed
|
Monitor for general drug reactions
|
Pregnancy
Pregnancy
Lactation
Special Use
Precaution
Overdose
Pharmacology
Storage
Do not store above 25°C. Protect from light. Keep out of reach of children.
Data Sources
Clinical & regulatory information on this page is compiled from the following government sources:
DISCLAIMER: This drug information content is provided for informational purposes only and is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Patients should always consult their physician with any questions regarding a medical condition and to obtain medical advice and treatment.